MTD

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

Mettler-Toledo International Inc. to Host First Quarter 2024 Earnings Conference Call

Retrieved on: 
Tuesday, April 9, 2024
Machine Tools, Metalworking & Metallurgy, Engineering, Chemicals, Plastics, Aerospace, Manufacturing, Other Manufacturing, Machinery, Quality control, MTD, Food, Mettler Toledo

Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024.

Key Points: 
  • Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024.
  • The Company will host a conference call the following morning at 8:30 a.m. Eastern Time to discuss the results.
  • To listen to the live audio webcast of the call, visit Events and Presentations on the Investor section of the Company’s website, investor.mt.com .
  • With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance.

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, March 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Retrieved on: 
Friday, March 15, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, SOC, MCL, Index, DHL, Patient, Neoplasm, Artificial intelligence, AI, Sarcoma, Human, NHL, Mantle cell lymphoma, Clinical trial, Bone marrow, Safety, Pharmacokinetics, MTD, Machine learning, FDA, DLBCL, Pharmaceutical industry

“Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.

Key Points: 
  • “Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.
  • Patients will be enrolled and treated with LP-284 administered intravenously (IV) on Days 1, 8, 15 of a 28-day schedule.
  • Up to 30 patients will be enrolled in Phase 1a; the total number of patients will depend on the number of dose levels explored.
  • Additionally, Lantern may enroll up to 40 patients in each of the two cohorts of MCL and HGBL (including DLBCL) tumors in Phase 1b.

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

Zimperium Takes Home the Gold in the 2024 Globee® Awards for Cybersecurity

Retrieved on: 
Thursday, March 14, 2024
MTD, Glass, Mobile security, Risk management, MAPS, Mobile phone

DALLAS, March 14, 2024 /PRNewswire/ -- Zimperium , the only mobile-first security platform for mobile devices and mobile apps, announced today that it has been honored as a Gold Globee winner in both Mobile Security and Mobile Application Security in the 20th Annual 2024 Globee Cybersecurity Awards.

Key Points: 
  • DALLAS, March 14, 2024 /PRNewswire/ -- Zimperium , the only mobile-first security platform for mobile devices and mobile apps, announced today that it has been honored as a Gold Globee winner in both Mobile Security and Mobile Application Security in the 20th Annual 2024 Globee Cybersecurity Awards.
  • The Globee Cybersecurity Awards spotlight the achievements of companies and individuals excelling in risk management, threat detection, cloud security, data privacy, and beyond.
  • "Congratulations to the 2024 victors for their pivotal role in fortifying our digital world," says San Madan, President of Globee Awards.
  • "We believe this recognition from Globee Awards further validates our commitment to our customers and their mobile security needs."